Category Archives: Clinical Trials & Medical Discoveries

Wize Pharma Receives IRB Approval of Phase IV Study Protocol for LO2A in Symptomatic Treatment of Dry Eye Syndrome in Patients With Sjögren's Syndrome

Posted on in Clinical Trials & Medical Discoveries, Finance News | 0 comments

HOD HASHARON, Israel, Feb. 20, 2018 /PRNewswire/ — Wize Pharma, Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, today announced it has received Institutional Review Board (IRB) approval for the protocol of its planned Phase IV study. This will be a Phase IV randomized, double-blind, placebo-controlled study of LO2A…

AbbVie Presents New Late-Breaking Phase 2b Data on Upadacitinib in Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting

Posted on in Clinical Trials & Medical Discoveries, Finance News | 0 comments

NORTH CHICAGO, Ill., Feb. 17, 2018 /PRNewswire/ — AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today presented new positive results from a Phase 2b dose-ranging study evaluating upadacitinib, an investigational, once-daily oral JAK1-selective inhibitor, in adult patients with moderate to severe atopic dermatitis. These results were featured during the “Late-Breaking Research: Clinical Trials”…

Evolus Announces Presentation of Phase III European – Canadian Comparative Data

Posted on in Clinical Trials & Medical Discoveries, Finance News | 0 comments

IRVINE, Calif., Feb. 17, 2018 /PRNewswire/ — Evolus, Inc. (NASDAQ: EOLS) today announced the presentation of data from the Phase III comparative clinical trial of its investigational prabotulinumtoxinA 900 kilodalton (kDa) neuromodulator at the American Academy of Dermatology (AAD) meeting.

Lumenis presenta la tecnología de PicoFractional™ en la reunión anual de AAD

Posted on in Clinical Trials & Medical Discoveries, Finance News | 0 comments

SAN DIEGO, February 14, 2018 /PRNewswire/ — – Lumenis tiene experiencia acústica y de calor y presenta la tecnología de PicoFractional™ en la reunión anual de la American Academy of Dermatology (AAD)

Lilly Announces Positive Top-Line Phase 3 Results for Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)

Posted on in Clinical Trials & Medical Discoveries, Finance News, Surveys, Polls and Research | 0 comments

INDIANAPOLIS, Feb. 13, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that Taltz® (ixekizumab) met the primary and all key secondary endpoints in COAST-V, a Phase 3 study evaluating the safety and efficacy of Taltz for the treatment of Ankylosing Spondylitis (AS), also known as radiographic axial spondyloarthritis (axSpA). The trial included a placebo arm…

Audentes Therapeutics Announces Selection of Optimized Clinical Development Candidate for Pompe Disease Program

Posted on in Clinical Trials & Medical Discoveries, Finance News, Trade Show News | 0 comments

SAN FRANCISCO, Feb. 6, 2018 /PRNewswire/ — Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced it has selected an optimized clinical development candidate for its Pompe disease program.  Data supporting the selection were presented today during a general session…

Sangamo Therapeutics Presents Initial Safety Data from CHAMPIONS Genome Editing Study for MPS II at WORLDSymposium

Posted on in Clinical Trials & Medical Discoveries, Finance News | 0 comments

RICHMOND, Calif., Feb. 6, 2018 /PRNewswire/ — Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced the presentation of initial safety data from the CHAMPIONS Study, the Phase 1/2 clinical trial evaluating SB-913 for the treatment of mucopolysaccharidosis (MPS) type II, a rare disease also known as Hunter syndrome. The data are being presented this afternoon at the 2018 WORLDSymposium…

Measuring the risks and rewards of drug development: New research from MIT shows that the success rates of clinical trials are higher than previously thought

Posted on in Clinical Trials & Medical Discoveries, Finance News, Surveys, Polls and Research | 0 comments

CAMBRIDGE, Mass., Jan. 31, 2018 /PRNewswire-USNewswire/ — A new study* by researchers at the Massachusetts Institute of Technology found that nearly 14% of all drugs in clinical trials eventually win approval from the FDA—an amount that is much higher than previous studies indicate. The researchers also found that approval rates for specific illnesses range from a…

Combination of Encorafenib, Binimetinib and Cetuximab Demonstrated an 8 Month Median Progression-Free Survival in BRAF-Mutant Colorectal Cancer in Updated Safety Lead-In Results from BEACON Phase 3 Trial

Posted on in Clinical Trials & Medical Discoveries, Finance News | 0 comments

BOULDER, Colo. and CASTRES, France, Jan. 20, 2018 /PRNewswire/ — Array BioPharma Inc. (Nasdaq: ARRY) and Pierre Fabre today announced updated results from the 30 patient safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with…

Combination of Encorafenib, Binimetinib and Cetuximab Demonstrated an 8 Month Median Progression-Free Survival in BRAF-Mutant Colorectal Cancer in Updated Safety Lead-In Results from BEACON Phase 3 Trial

Posted on in Clinical Trials & Medical Discoveries, Finance News | 0 comments

BOULDER, Colo. and CASTRES, France, Jan. 20, 2018 /PRNewswire/ — Array BioPharma Inc. (Nasdaq: ARRY) and Pierre Fabre today announced updated results from the 30 patient safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with…